Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaxem Hib vs Hiberix Booster in Chinese Toddlers
NCT01025544Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2009
- Primary completion
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of VaxemHIB in Haemophilus influenzae type b infection (Hib) (2 arms), sponsored by Novartis. Primary endpoint: Anti-PRP antibody levels at 31 days. Started Sep 2009; status: completed.
02
Drugs
VaxemHIB
03
Conditions
Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT01025544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01025544.